Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31226082 | 1.00 | GAA (0.41) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL1189327 | 0.75 | MAPT (0.43) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL11822056 | 0.72 | TDP1 (0.54) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL11833039 | 0.72 | GAA (0.41) | GAAMAPTALDH1A1KDM4EHTT | |
| Hydrazine SCHEMBL3661754 | 0.72 | ALDH1A1 (0.41) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL31226080 | 0.72 | TDP1 (0.46) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL992647 | 0.72 | TDP1 (0.46) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL1189496 | 0.71 | GAA (0.39) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL9907139 | 0.71 | GAA (0.39) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL2646767 | 0.71 | GAA (0.39) | GAAMAPTALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024245156-A1 | HETEROCYCLIC COMPOUND ACTING AS α5-GABAA RECEPTOR REGULATOR | 武汉人福创新药物研发中心有限公司 | 2024-12-05 | — | — | WO | disclosed |
| US-8993570-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993570-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130317033-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8501738-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501738-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2454259-A1 | DEUTERIUM-MODIFIED TRIAZOLO-PYRIDAZINE DERIVATIVES AS GABA-A RECEPTOR MODULATORS | Concert Pharmaceuticals Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110065711-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2011005520-A1 | DEUTERIUM-MODIFIED TRIAZOLO-PYRIDAZINE DERIVATIVES AS GABA-A RECEPTOR MODULATORS | CONCERT PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-6828322-B2 | Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine | MERCK SHARP & DOHME LTD. | 2004-12-07 | — | — | US | disclosed |
| US-20040063714-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| US-6579875-B1 | Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine | MERCK SHARP & DOHME LIMITED | 2003-06-17 | — | — | US | disclosed |
| CN-1110498-C | Triazolo-pyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME (GB) | 2003-06-04 | — | — | CN | disclosed |
| EP-1107967-B1 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR ENHANCING COGNITION | MERCK SHARP & DOHME (GB) | 2003-05-14 | — | — | EP | disclosed |
| EP-1107967-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LTD. (GB) | 2001-06-20 | — | — | EP | disclosed |
| CN-1288465-A | Triazolo-pyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME (GB) | 2001-03-21 | — | — | CN | disclosed |
| EP-1049696-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000012505-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999037644-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063714-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | GABRA3, GABBR1, GABRA2 | GAA 4157/4885MAPT 1105/4885ALDH1A1 1373/4885 |
| US-20130317033-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, GABRA2, GABRA3 | GAA 2767/4885MAPT 1095/4885ALDH1A1 1152/4885 |
| US-20110065711-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, GABRA2, GABRA3 | GAA 2767/4885MAPT 1095/4885ALDH1A1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.